Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
PharmacoEconomics
Erschienen in: PharmacoEconomics 1/2001

01.11.2001 | Original Research Article

A Framework for Evaluating the Clinical Consequences of Initial Therapy with NSAIDs, NSAIDs plus Gastroprotective Agents, or Celecoxib in the Treatment of Arthritis

verfasst von: Thomas A. Burke, Richard A. Zabinski, Daniel Pettitt, Nikos Maniadakis, Clement J. Maurath, Jay L. Goldstein

Erschienen in: PharmacoEconomics | Sonderheft 1/2001

Einloggen, um Zugang zu erhalten

Abstract

Objective: The purpose of this study is to provide a framework for estimating the economic efficiency of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), concomitant gastroprotective agents (GPAs) to reduce the risk of NSAID toxicity, and celecoxib, a specific cyclo-oxygenase-2 inhibitor. Concomitant GPAtherapies considered include one of the following: proton pump inhibitors (PPIs) plus NSAIDs, histamine H2 receptor antagonists (H2RAs) plus NSAIDs, misoprostol plus NSAIDs, and a single tablet formulation of diclofenac/misoprostol.
Design: The study employs a decision-tree framework to establish probabilities of upper gastrointestinal (GI) adverse events occurring over a 6-month time frame. Celecoxib clinical trial data are used to establish probabilities of upper GI events for celecoxib and NSAIDs, and published literature is used to predict upper GI events for the other concomitant therapies. Upper GI adverse events included in the decision-tree are as follows: GI discomfort, symptomatic ulcer, serious GI complications (with and without death), and anaemia with occult bleeding.
Main outcome measures and results: Clinical probabilities indicate celecoxib has significant tolerability and safety advantages compared with nonselective NSAIDs. Celecoxib also reduces the risk of GI adverse events to a similar or superior degree when compared with reductions observed with NSAIDs with concomitant GPAs.
Conclusion: Use of celecoxib is expected to significantly reduce the economic costs of GI toxicity and its associated morbidity.
Literatur
1.
Singh G, Ramey DM, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch Intern Med 1996; 156: 1530–6PubMedCrossRef
2.
Wynne H, Campbell M. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs). Pharmacoeconomics 1993; 3 (2): 107–23PubMedCrossRef
3.
Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or the hip: a randomised, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J Rheumatol 1998; 25 (8): 1602–11PubMed
4.
MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333–7PubMedCrossRef
5.
Wolfe MM, Lichtenstein DR, SinghG. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99PubMedCrossRef
6.
Singh G. Recent considerations in non-steroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105 (1B): 31S-8CrossRef
7.
Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123 (4): 241–9PubMed
8.
Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769–72PubMedCrossRef
9.
Edelson JT, Tosteson AN, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990; 264 (1): 41–7PubMedCrossRef
10.
Singh G, Rosen RD. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl. 1998 May; 51: 8–16PubMed
11.
Goldstein JL, Larson LR, Yamashita BD, et al.Management of NSAID-induced gastropathy: an economic decision analysis. Clin Ther 1997; 19 (6): 1496–509PubMedCrossRef
12.
Bloor K, Maynard A. Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs? Pharmacoeconomics 1996; 9 (6): 484–96PubMedCrossRef
13.
Garcia-Rodriguez LA, Walker AM, Gutthann SP. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992; 3: 337–42PubMedCrossRef
14.
Simon LS, Zhao SZ, Arguelles L, et al. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis. Clin Ther 1998; 20 (6): 1218–35PubMedCrossRef
15.
Hogan DB, Campbell NR, Crutcher R, et al. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. CMAJ 1994; 151 (3): 315–22PubMed
16.
17.
Ehsanullah RSB, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988; 297: 1017–21PubMedCrossRef
18.
Robinson MG, Griffin Jr JW, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiiflammatory drugs. Dig Dis Sci 1989; 34 (3): 424–8PubMedCrossRef
19.
Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1993; 153: 2449–54PubMedCrossRef
20.
Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334 (22): 1435–9PubMedCrossRef
21.
Agrawal NM, Van-Kerckhove HE, Erhardt LJ, et al. Misoprostol coadministeredwith diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci 1995; 40 (5): 1125–31PubMedCrossRef
22.
Elliott SL, Yeomans ND, Buchanan RRC, et al. Efficacy of 12 months’ misoprostol as prophylaxis against NSAID-induced gastric ulcers. Scand J Rheumatol 1994; 23 (4): 171–6PubMedCrossRef
23.
Graham DY, Smith JL. Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol 1988; 83 (10): 1081–4PubMed
24.
Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119 (4): 257–62PubMed
25.
Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338 (11): 727–34PubMedCrossRef
26.
Hudson N, Taha AS, Russell RI. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112 (6): 1817–22PubMedCrossRef
27.
Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123 (5): 344–50PubMed
28.
Roth SH. Misoprostol in the prevention of NSAID-Induced gastric ulcer: a multicenter, double-blind, placebo-controlled trial. J Rheumatol 1990; 20: 20–4
29.
Drummond M, O’Brien B, Stoddart G, et al., editors. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997: 281–4
30.
Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998; 41 (1): 16–25PubMedCrossRef
31.
Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Arch Intern Med 1994; 154 (18): 2020–5PubMedCrossRef
32.
Gabriel SE, Jaakkimainen L, Bombardier C. The cost effectiveness of misoprostol for nonsteroidal antiinflammatory drug associated adverse gastrointestinal events. Arthritis Rheum 1993; 36 (4): 447–59PubMedCrossRef
33.
Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061–5PubMedCrossRef
34.
Jonsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care 1992; 8 (2): 234–44PubMedCrossRef
35.
Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990; 66 (778): 639–46PubMedCrossRef
36.
Al MJ, Michel BC, Rutten FFH. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. Pharmacoeconomics 1996; 10: 141–51PubMedCrossRef
37.
Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74 (11): 1095–105PubMedCrossRef
38.
Simon LS, Weaver AL, Graham DY, et al. The anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921–8PubMedCrossRef
39.
Bensen W, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27: 1876–83PubMed
40.
41.
Cullen D, Bardhan KD, EisnerM, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12 (2): 135–40PubMedCrossRef
42.
Ekström P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31 (8): 753–8PubMedCrossRef
43.
Rugstad HE, Giercksky KE, HusbyG, et al. Effect of cimetidine on gastrointestinal symptoms in patients taking nonsteroidal anti-inflammatory drugs. A large double-blind placebo controlled study. Scand J Rheumatol 1994; 23 (4): 177–82PubMedCrossRef
44.
Melo-Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/ misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52 (12): 881–5PubMedCrossRef
45.
Verdickt W, Moran C, Hantzschel H, et al. Adouble-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992; 21 (2): 85–91PubMedCrossRef
46.
Bolten W, Gomes JA, Stead H, et al. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992; 31 (11): 753–8PubMedCrossRef
47.
Agrawal NM, Caldwell JC, Kivitz AJ, et al. Comparison of the upper gastrointestinal safety of Arthrotec® 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 1999; 21 (4): 659–74PubMedCrossRef
48.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (3): 177–88PubMedCrossRef
49.
Barbara L, Camilleri M, Corinaldesi R, et al. Definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig Dis Sci 1989; 34 8): 1272–6PubMedCrossRef
50.
Colin-Jones D, Bloom B, Bodemar G, et al. Management of dyspepsia: report of a working party. Lancet 1988; 1: 576–9
51.
Kuykendall DH, Rabeneck L, Campbell CJM, et al. Dyspepsia: how should we measure it? J Clin Epidemiol 1998; 51 (2): 99–106PubMedCrossRef
52.
Shallcross T, Heatley RV. Effect of non-steroidal anti-inflammatory drugs on dyspeptic symptoms. BMJ 1990; 300: 368–9PubMedCrossRef
53.
Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102 (4 Pt 1): 1259–68PubMed
54.
Perez-Gutthann S, Garcia-Rodriguez LA, Duque-OliartA, et al. Low-dose diclofenac, naproxen, and ibuprofen cohort study. Pharmacotherapy 1999; 19: 854–9PubMedCrossRef
55.
Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflamatory drug-associated gastropathy: incidence and risk factors. Am J Med 1991; 91: 213–22PubMedCrossRef
56.
Gutthann SP, Garcia-Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8 (1): 18–24PubMedCrossRef
57.
Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalisation for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists and other antihypertensive drugs. Arch Intern Med 1998; 158 (1): 33–9PubMedCrossRef
58.
Langman MJ. Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med 1988; 84 (2A): 15–9PubMedCrossRef
59.
Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response. Arch Intern Med 1987; 147 (12): 2093–100PubMedCrossRef
60.
Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastroenterology. 1989; 96 (2 Pt 2 Suppl.): 675–81PubMed
61.
Cucala M, Bauerfeind P, Emde C, et al. It is wise to prescribe NSAIDs with modern gastroprotective agents? Scand J Rheumatol Suppl. 1987; 65: 141–54PubMedCrossRef
62.
Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001; 19 Suppl. 1: 49–58PubMedCrossRef
63.
Chevat C, Peña BM, Al MJ, et al. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity: a multinational perspective. Pharmacoeconomics 2001; 19 Suppl. 1: 17–32PubMedCrossRef
64.
Hunsche E, Chancellor JVM, Bruce N. The burden of arthritis and nonsteroidal anti-inflammatory treatment: a European literature review. Pharmacoeconomics 2001; 19 Suppl. 1: 1–15PubMedCrossRef
65.
Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 115 (10): 787–96PubMed
66.
Griffin M, Piper J, Daugherty J, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114 (4): 257–63PubMed
67.
Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8PubMedCrossRef
68.
Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal antiinflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141 (6): 539–45PubMed
69.
Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82 (11): 1153–8PubMed
70.
Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995; 40 (6): 1345–50PubMedCrossRef
71.
Straus W, Ofman J, MacLean C, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative definitions [abstract no. 277]. Program Book of Digestive Diseases Week (DDW); 1999 May 16–19; Orlando, Florida, USA: A-50
72.
Paulus HE. FDA Arthritis Advisory Committee Meeting: serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs; drug-containing renal and biliary stones; diclofenac and carprofen approved. Arthritis Rheum 1988; 31 (11): 1450–1CrossRef
73.
Lanza FL. Prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions: a commentary on the new data. Am J Med 1998; 104 (3A): 75S-8CrossRef
74.
Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827–30PubMedCrossRef
75.
Henry D, Lim LL, Garcia-Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563–6PubMedCrossRef
76.
Carson JL, Willett LR. Toxicity of nonsteroidal anti-inflammatory drugs. An overview of the epidemiological evidence. Drugs 1993; 46 (Suppl. 1): 243–8PubMedCrossRef
77.
Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000; 27 (7): 1668–73PubMed
Metadaten
Titel
A Framework for Evaluating the Clinical Consequences of Initial Therapy with NSAIDs, NSAIDs plus Gastroprotective Agents, or Celecoxib in the Treatment of Arthritis
verfasst von
Thomas A. Burke
Richard A. Zabinski
Daniel Pettitt
Nikos Maniadakis
Clement J. Maurath
Jay L. Goldstein
Publikationsdatum
01.11.2001
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe Sonderheft 1/2001
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200119001-00003

Weitere Artikel der Sonderheft 1/2001

PharmacoEconomics 1/2001 Zur Ausgabe

Original Research Article

Healthcare Resource Utilisation and Costs of Treating NSAID-Associated Gastrointestinal Toxicity

Review Article

The Burden of Arthritis and Nonsteroidal Anti-Inflammatory Treatment

Original Research Article

Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland

Original Research Article

An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada